HALOZYME THERAPEUTICS, INC. · Exercise / conversion · Common Stock

What does this filing report?

An SEC Form 4 filing for HALOZYME THERAPEUTICS, INC. records an exercise / conversion involving Common Stock on November 11, 2025. The reported quantity was 20,000. The filing date is November 12, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Filing footnotes & remarks

F1

The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026.

F2

Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.250 to $69.180. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3

Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.395 to $68.360. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4

Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.400 to $69.350. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F5

Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.400 to $69.940. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F6

Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.570 to $70.565. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F7

Represents a weighted average sales price per share. The shares were sold at prices ranging from $70.570 to $71.560. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F8

Represents a weighted average sales price per share. The shares were sold at prices ranging from $71.575 to $71.730. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F9

Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.